AUTHORS
Xingnong Ye, Xiang Zhang2, Yufei Lv3, Juying Wei4, Jie Jin, MD5, Liping Mao6, Chunmei Yang, MD7, Wen-Juan Yu, MD8
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
7 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
ABSTRACT
Background: Chemoimmunotherapy is effective for previously untreated follicular lymphoma (FL) but is associated with hematologic toxicity, infection risk, and cumulative treatment burden. The RELEVANCE study established immunomodulatory therapy combined with an anti-CD20 antibody as a chemotherapy-free frontline strategy. Pomalidomide, a next-generation immunomodulatory agent, may enhance T-cell and natural killer-cell function and potentiate anti-CD20-mediated cytotoxicity. In addition, the activity of zanubrutinib plus obinutuzumab in relapsed or refractory FL provides a rationale for evaluating this combination in an earlier treatment setting. We therefore investigated obinutuzumab, pomalidomide, and zanubrutinib as a chemotherapy-free frontline regimen targeting FL cells, B-cell receptor signaling, and the immune microenvironment.
Aim: To evaluate the efficacy and safety of obinutuzumab, pomalidomide, and zanubrutinib as first-line therapy for patients with FL.
Methods: This investigator-initiated, prospective,single-arm phase 2 study enrolled patients with previously untreated, CD20-positive follicular lymphoma requiring systemic therapy who were aged ≥60 years or declined chemotherapy. Patients received six 28-day cycles of obinutuzumab, pomalidomide, and zanubrutinib, followed by six cycles of pomalidomide and zanubrutinib maintenance in patients achieving at least a partial response. The primary endpoint was complete response rate after 6 cycles. Responses were assessed by PET/CT according to the Lugano 2014 criteria, and adverse events were graded using CTCAE v5.0.
Results: As of July 2026, 35 patients had been enrolled. The median age was 50 years (range, 27–74), and 34 patients (97.1%) had an Eastern Cooperative Oncology Group performance status of 0–1. Ten patients (28.6%) had a high-risk Follicular Lymphoma International Prognostic Index score, and 31 (88.6%) had Ann Arbor stage III–IV disease. B symptoms were present in 9 patients (25.7%), extranodal involvement in 17 (48.6%), and bone marrow involvement in 15 (42.9%).
At the data cutoff, 25 patients had completed four treatment cycles, of whom 19 had an available cycle 4 response assessment. All 19 patients responded, including 13 complete responses (CRs) and 6 PRs, corresponding to an overall response rate (ORR) of 100% and a CRR of 68.4%. Nineteen patients had completed six treatment cycles, of whom 16 had an available response assessment by completion of cycle 6 and were included in the preliminary primary-endpoint analysis. Fourteen patients achieved CR and 2 achieved PR, resulting in an ORR of 100% and a preliminary CRR of 87.5%.
Nineteen patients had completed six treatment cycles, of whom 16 had an available response assessment by completion of cycle 6 and were included in the preliminary primary-endpoint analysis. Fourteen patients achieved CR and 2 achieved PR, resulting in an ORR of 100% and a preliminary CRR of 87.5%.Overall, 21 patients (60.0%) experienced treatment-emergent AEs, including 10 (28.6%) with grade ≥3 events. The most common AEs were neutropenia (34.3%; grade ≥3, 22.9%), thrombocytopenia (20.0%), anemia (17.1%), infection (17.1%), and rash (17.1%). No grade 5 AEs were reported.
Conclusions: Preliminary results suggest that obinutuzumab, pomalidomide, and zanubrutinib is an active chemotherapy-free frontline regimen for FL, with a high CRR among patients who completed six cycles and a manageable early safety profile. The primary endpoint analysis is not yet mature, and longer follow-up is needed to determine the durability of response, progression-free survival, and longer-term safety.
DISCLOSURES
Xingnong Ye: No relevant conflicts of interest to declare.